Roivant Sciences (ROIV) Cash from Investing Activities (2020 - 2025)
Roivant Sciences (ROIV) posted Cash from Investing Activities of -$855.8 million for Q4 2025, down 810.69% on a QoQ basis from $120.4 million in Q3 2025, and up 69.87% year-over-year from -$503.8 million in Q4 2024.
Roivant Sciences (ROIV) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Roivant Sciences' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$855.8 million for Q4 2025.
- Quarterly Cash from Investing Activities rose 69.87% year-over-year to -$855.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.7 billion (down 396.79% YoY) and the FY2026 annual result came in at -$682.3 million, up 61.37% from the prior year.
- Cash from Investing Activities was -$855.8 million for Q4 2025 at Roivant Sciences, down from $120.4 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5.2 billion in Q4 2023 and bottomed at -$3.3 billion in Q3 2024.
- A 5-year average of -$165.6 million and a median of -$7.5 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 3392.76% — and 2025, when it slumped 112409.43%.
- Roivant Sciences' Cash from Investing Activities stood at $309.0 million in 2021, then tumbled by 151.08% to -$157.8 million in 2022, then surged by 3392.76% to $5.2 billion in 2023, then slumped by 154.66% to -$2.8 billion in 2024, then surged by 69.87% to -$855.8 million in 2025.
- Business Quant data shows ROIV's Cash from Investing Activities at -$855.8 million in Q4 2025, $120.4 million in Q3 2025, and -$1.1 billion in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Roivant Sciences | 24.03 Bn | 24.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -855.82 Mn |
| Dec 31, 2025 | -855.82 Mn |
| Sep 30, 2025 | 120.42 Mn |
| Sep 30, 2025 | 120.42 Mn |
| Jun 30, 2025 | -1.09 Bn |
| Jun 30, 2025 | -1.09 Bn |
| Dec 31, 2024 | -2.84 Bn |
| Dec 31, 2024 | -2.84 Bn |
| Sep 30, 2024 | -3.29 Bn |
| Sep 30, 2024 | -3.29 Bn |
| Jun 30, 2024 | -965,000.00 |
| Jun 30, 2024 | -965,000.00 |
| Dec 31, 2023 | 5.20 Bn |
| Dec 31, 2023 | 5.20 Bn |
| Sep 30, 2023 | -36.45 Mn |
| Sep 30, 2023 | -36.45 Mn |
| Jun 30, 2023 | 105,000.00 |
| Jun 30, 2023 | 105,000.00 |
| Dec 31, 2022 | -157.82 Mn |
| Dec 31, 2022 | -157.82 Mn |